Endometrial cancer represents the most prevalent gynecologic malignancy in high-income regions, where its management conventionally hinges on ...

In the article that accompanies this editorial, Sicklick et al 2 provide the results of their work to match next-generation sequencing to novel therapeutic drugs/combinations in patients with ...

Targeted Oncology: For the community oncologist, the choice between niraparib and olaparib often comes down to the patient's molecular profile. In a pMMR/HRD-negative patient, what clinical markers ...

A growing body of research is pushing cancer science toward a radical shift: detecting and stopping the disease years or even decades before a tumor ever forms. Multiple studies now show that ...

NEW YORK, Jan. 12, 2026 /PRNewswire/ -- The Center for Molecular Oncology at NYU Langone Health's Perlmutter Cancer Center will soon launch a new protocol for patients diagnosed with early-stage and ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...

Real-time clinical validation of a blood cell-free, mRNA-based GeneVerify test for screening and early diagnosis of prostate cancer. Circulating tumor DNA and late recurrence in high-risk, hormone ...

Please provide your email address to receive an email when new articles are posted on . In this video, Robert DeBernardo, MD, discusses the prognostic potential of molecular profiling to treat ...

Biomarker testing for 11 oncogenes at diagnosis enables personalized lung cancer treatment, moving away from a one-size-fits-all approach. Biomarkers serve diagnostic, prognostic, and predictive roles ...

When Ginny Mason was diagnosed with inflammatory breast cancer in 1994, she never once heard the word “biomarker.” “Back then, all you got was ER and PR [the estrogen receptor and progesterone ...